---
schema_version: "secwatch.filing_event.v1"
accession: "0001555280-23-000072"
form_type: "8-K"
ticker: "ZTS"
cik: "0001555280"
company_name: "Zoetis Inc."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:45:56.884072+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zoetis Q4 revenue $2.0B (+9% operational); adj. EPS $1.15; FY23 guide $8.575-8.725B

## Summary
- Q4 revenue $2.0B (+4% reported, +9% operational); net income $461M ($0.99 EPS); adj. net income $539M ($1.15 adj. EPS).
- Full year 2022 revenue $8.1B (+4% reported, +8% operational); adj. net income $2.3B ($4.88 adj. EPS).
- U.S. segment revenue $1.112B (+7%), driven by Simparica Trio and dermatology brands Apoquel and Cytopoint.
- International segment revenue $901M (flat reported, +12% operational), led by parasiticides and dermatology.
- FY23 guidance: revenue $8.575-8.725B (6-8% operational growth); adj. diluted EPS $5.34-5.44.

## SEC filing metadata
- accession: 0001555280-23-000072
- form_type: 8-K
- ticker: ZTS
- cik: 0001555280
- company_name: Zoetis Inc.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/0001555280-23-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/zts-20230214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001555280-23-000072
- JSON: https://secwatch.observer/filing/0001555280-23-000072.json
- Plain text: https://secwatch.observer/filing/0001555280-23-000072.txt

## Key facts
- Earnings Releases
  Zoetis Inc. reported Full Year 2023 results: revenue $8.575 - $8.725 Billion, EPS $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis. Guidance initiated.
  - Period: Full Year 2023
  - Revenue: $8.575 - $8.725 Billion
  - EPS: $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis
  - Guidance: initiated
  - Result: guidance update
  source text: Provides Full Year 2023 Revenue Guidance of $8.575 - $8.725 Billion, with Diluted EPS of $5.03 to $5.14 on a Reported Basis, or $5.34 to $5.44 on an Adjusted Basis
  evidence_url: https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/0001555280-23-000072-index.htm
- Earnings Releases
  Zoetis Inc. reported Full Year 2022 results: revenue $8.1 Billion, net income $2.1 Billion, or $4.49 per Diluted Share.
  - Period: Full Year 2022
  - Revenue: $8.1 Billion
  - Net income: $2.1 Billion, or $4.49 per Diluted Share
  - Result: reported results
  source text: For Full Year 2022, Zoetis Reports Revenue of $8.1 Billion, Growing 4%, and Net Income of $2.1 Billion, or $4.49 per Diluted Share, on a Reported Basis
  evidence_url: https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/0001555280-23-000072-index.htm
- Earnings Releases
  Zoetis Inc. reported the fourth quarter and full year 2022 results: revenue $2.0 Billion, net income $461 Million, or $0.99 per Diluted Share. Guidance initiated.
  - Period: the fourth quarter and full year 2022
  - Revenue: $2.0 Billion
  - Net income: $461 Million, or $0.99 per Diluted Share
  - Guidance: initiated
  - Result: reported results
  source text: specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Zoetis Reports Fourth Quarter and Full Year 2022 Results • For Fourth Quarter 2022, Zoetis Reports Revenue of $2.0 Billion, Growing 4%, and Net Income of $461 Million, or $0.99 per Diluted Share, on a Reported Basis ◦ Delivers 9% Operational Growth in Revenue and 27% Operational Growth in Adjusted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1555280/000155528023000072/0001555280-23-000072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.